Conditions: Melanoma Metastatic
Keywords: Melanoma Metastatic
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether dacarbazine and carmustine at the doses and schedule used in this study will help to increase tumor shrinkage.

Detailed description:
In this phase II trial, patients with stage IV melanoma will be treated with dacarbazine and carmustine commonly used in this cancer, but given using a schedule that might theoretically improve on this combination. Patients on this study will be assessed in terms of toxicity, response rate, median duration of response, median time to disease progression, and median survival.

Arms:
arm 1: Dacarbazine IV - Day 1; Carmustine IV - Day 2; Neulasta SC - Day 3

Interventions: intervention 1: Dacarbazine intervention 2: Carmustine intervention 3: Neulasta
Intervention descriptions: intervention 1: Dacarbazine IV - Day 1 intervention 2: Carmustine IV- Day 2 intervention 3: Neulasta SC - Day 3

Protocol document: